Evidence map›Paper›PMID 42117428›Full record

ArticleBrain : a journal of neurology2026

White matter lesions disrupt cholinergic pathways important for cognition in Parkinson's disease.

Giulia Carli, Taylor Brown, Fotini Michalakis, Abigail Biddix, Stiven Roytman, Robert Vangel, August Van Hout, Prabesh Kanel, Peter Scott, Roger L Albin and 1 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giulia CarliDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.
Taylor BrownFunctional Neuroimaging, Cognitive, and Mobility Laboratory, Department of Radiology, Ann Arbor, MI 48106, University of Michigan.
Fotini MichalakisFunctional Neuroimaging, Cognitive, and Mobility Laboratory, Department of Radiology, Ann Arbor, MI 48106, University of Michigan.
Abigail BiddixFunctional Neuroimaging, Cognitive, and Mobility Laboratory, Department of Radiology, Ann Arbor, MI 48106, University of Michigan.
Stiven RoytmanFunctional Neuroimaging, Cognitive, and Mobility Laboratory, Department of Radiology, Ann Arbor, MI 48106, University of Michigan.
Robert VangelFunctional Neuroimaging, Cognitive, and Mobility Laboratory, Department of Radiology, Ann Arbor, MI 48106, University of Michigan.
August Van HoutFunctional Neuroimaging, Cognitive, and Mobility Laboratory, Department of Radiology, Ann Arbor, MI 48106, University of Michigan.
Prabesh KanelMorris K. Udall Center of Excellence for Parkinson's Disease Research, University of Michigan, Ann Arbor, MI 48109, USA.
Peter ScottDepartment of Radiology, University of Michigan, Ann Arbor, MI 48109, USA.
Roger L AlbinDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.
Nicolaas I BohnenDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-0352-6414

Funding

Udall Catalyst Research Project: Retrosplenial Cholinergic and Attentional-Motor Integration DysfunctionP50NS123067 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI AHMED, OMAR JAMIL · 2021 to 2025
$11.6M
Public Outreach and Education CoreP50NS091856 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALBIN, ROGER L · 2014 to 2019
$10.1M
Central cholinergic presbyvestibulopathy network changes and imbalance in Parkinson's disease and older personsR01AG073100 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BOHNEN, NICOLAAS IDA · 2021 to 2025
$3.0M
Exploring Cholinergic Changes and their Associations with Sleep Alterations in the Lewy Body Disease Spectrum: New Biomarkers and Therapeutic TargetsK99NS146570 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Giulia Carli · 2026 to 2026
$128k
NIA NIH HHS R01 AG073100NINDS NIH HHS K99 NS146570NINDS NIH HHS P50 NS091856NINDS NIH HHS P50 NS123067RRD VA I01 RX001631RRD VA I01 RX003397
6 · The paper itself

Abstract

White matter lesions are associated with cognitive impairment in Parkinson's disease, but the underlying neurobiological mechanisms remain unclear. One hypothesis is that strategically located white matter lesions disrupt long-range white-matter pathways crucial for cognitive functioning, particularly cholinergic projections from the basal forebrain, contributing to cognitive decline. Using volumetric measures of basal forebrain nuclei (T1 MRI proxy for brain cholinergic projection nuclei), quantitative white matter lesions assessments (fluid-attenuated inversion recovery MRI), and a presynaptic cholinergic marker ([18F]-FEOBV PET), we tested a mechanistic model of white matter lesions effects on basal forebrain cholinergic projections and nuclei, and how these disruptions relate to cognition. We analysed data from 127 mid to advanced-stage patients with Parkinson's disease without dementia. Periventricular and deep white matter lesion burdens were quantified with the UBO Detector pipeline. Cognitive function was assessed across five domains using z-scores from a control group matched for age and education. Voxel-wise analyses examined associations between white matter lesion burden and cholinergic synaptic density, followed by mediation analyses testing whether cholinergic alterations mediated the relationship between white matter lesions and cognition, while correcting for sex, levodopa equivalent dose, and disease duration. Voxel-wise analyses revealed that higher periventricular lesions burden was associated with reduced [18F]-FEOBV uptake in an insular-limbic-frontal-cingulum cluster, while deep lesions showed more topographically limited associations that disappeared after adjusting for periventricular burden. Periventricular lesions affected lateral and external Ch4 cholinergic projection pathways (81%-88% of patients), more frequently than deep white matter lesions (25%-47% of patients), except for the external capsule, which was equally affected by both. Cognitive performance (global cognition, memory, executive function, and attention) was associated with both periventricular lesion burden and [18F]-FEOBV uptake within the insular-limbic-frontal-cingulum cluster, as well as with basal forebrain volume. Mediation analyses indicated that periventricular lesions had a direct effect on cortical terminal integrity ([18F]-FEOBV) and an indirect, presumably retrograde degeneration effect via basal forebrain atrophy. The effect of periventricular lesions on insular-limbic-frontal-cingulum cholinergic terminal density was a strong mediator of the association between lesion burden and cognitive performance. A weaker mediation effect via the basal forebrain emerged for global cognition, whereas mediation was more robust for memory and executive functioning. Our findings indicate that periventricular white matter lesions contribute to cognitive vulnerability in Parkinson's disease without dementia through impacts on basal forebrain cholinergic projections. White matter lesion burden may represent a mechanistically meaningful biomarker for predicting cognitive trajectories and informing targeted interventions in Parkinson's disease.

Identifiers

PMID42117428
PMCPMC13626049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.